**Specifications Table**TableSubject areaImmunologyMore specific subject areaB cells in Rheumatoid ArthritisType of data1 figure, 3 tables, url to dataHow data was acquiredSequencing, patient clinical characteristics linked to experimental dataData formatAnalyzed, rawExperimental factorsFcRL4+ and FcRL4- B cells were sorted from synovial fluid and tissue from RA patients. Synovial fluid derived B cells were analysed for their gene expression profile by RNAseq. Immunoglobulin variable region genes from single sorted B cells were sequenced and expressed as components of recombinant monoclonal antibodies. These were investigated for their reactivity with autoantigens.Experimental featuresData shown here include detailed clinical characteristics from anonymized patients, the Ig isotype data generated from B cells sorted from four individual patients, tables detailing variable gene region sequences from sorted cells linked to the patient clinical characteristics and the sequence yields from individual patients. We also supply a URL link to the RNAseq datasets submitted to GEO.Data source locationBirmingham UKData accessibility<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE94897>Related research article1) Amara K, Clay E, Yeo L, Ramsköld D, Spengler J, Sippl N, Cameron JA, Israelsson L,Titcombe PJ, Grönwall C, Sahbudin I, Filer A,Raza K, Malmström V, Scheel-Toellner D.B cells expressing the IgA receptor FcRL4 participate in the autoimmune response in patients with rheumatoid arthritis. J Autoimmun. 2017. pii: S0896-8411(16)30396-1. doi: [10.1016/j.jaut.2017.03.004](http://10.1016/j.jaut.2017.03.004){#ir0010} \[Epub ahead of print\]

**Value of the data**•First RNAseq dataset from FcRL4+ and FcRL4- B cells sorted from the synovial fluid of patients with rheumatoid arthritis. This will be valuable to researchers interested in the regulation of B cell subpopulations and their functional role in RA.•Ig subclass distribution in FcRL4+ and FcRL4- B cells infiltrating the rheumatoid joint. This gives important information of the potential origins of these cells and their potential function in the joint.•The tables linking variable region sequences, gene usage, Ig isotypes and reactivity with citrullinated autoantigens give insight into the immune response to citrullinated proteins on a single cell basis.

1. Data {#s0005}
=======

The data shown in this manuscript have been generated in a study of FCRL4+ and FcRL4- B cells infiltrating the synovial fluid and synovial tissue of RA patients. They include a link to the GEO dataset of RNAseq gene expression profiles of these cells. Furthermore, the Ig isotype distribution of the B cells for these populations is shown for four individual patients in [Fig. 1](#f0005){ref-type="fig"}. [Table 1](#t0005){ref-type="table"} gives detailed clinical characteristics from the anonymized patients. These are linked to the data shown in [Table 2](#t0010){ref-type="table"}, detailing variable gene region sequences from sorted cells, the isotype usage and reactivity with citrullinated proteins of these individual cells. [Table 3](#t0015){ref-type="table"} displays the number of sequences and recombinant monoclonal antibodies generated from FcRL4+ and FcRL4- B cells from individual patients.Fig. 1Ig subclass distribution determined in single sorted FcRL4+ and FcRL4- B cells in four individual patients.Fig. 1Table 1Clinical characteristics of RA patients who provided synovial fluid or synovial tissue. RF, rheumatoid factor; CCP, cyclic citrullinated peptide; CRP, C reactive protein; ESR, erythrocyte sedimentation rate, DAS28, disease activity score 28, TJC, tender joint count, SJC swollen joint count, VAS visual analog score. Hydroxychlor., Hydroxychloroquine. NA not available.Table 1**Patient identifierSampleDiagnosisGenderAge (yrs)Age at onset of RADis. Dur. (yrs)RFCCPCRPESRDAS 28 ESRTJC (28)SJC (28)VAS gen. healthFiguresCurrent disease modifying therapy**1STRAF692742NApos0185.6123801A, 1B, 2A, 2B, 3A, 3B, 3C, 4A, 4BAdalimumab2STRAM705515pospos11243.8621401A, 1B, 2A, 2B, 3A, 3B, 3CEtanercept, Methotrexate, Hydroxychlor.3SFRAM72720.23negneg23306.01114491A, 1B, 2A, 2B, 3A, 3B, 3CNil4SFRAF524112negneg0385.452891A, 1B, 2A, 2B, 3A, 3B, 3CMethotrexate Tocilizumab5SFRAF40400.23pospos895.9198841A, 1B, 2A, 2B, 3A, 3B, 3C, 4A, 4BHydroxychlor.6SFRAF493811posna3153.12201A, 1B, 2A, 2B, 3A, 3B, 3CEtanercept, Methotrexate7SFRAM685612NANA1915NANANANA1CMethotrexate8SFRAF60519NApos4513NA6NANA1CMethotrexate9SFRAF44413negneg13294.9573451CMethotrexate10SFRAF60573pospos20557.051510851CNil11SFRAM39345NANANANANANANANA1CEtanercept12SFRAF70682posneg142214.852731CPrednisolone13SFRAF60573pospos1221045.8824911CSulfasalazine14SFRAF602931negpos57286.751611891CPrednisolone15SFRAF63621pospos30604.1312221CMethotrexate, prednisolone16SFRAM54540.23negneg88587.392312931CNil17SFRAF77689negneg7162NANANANA1CMethotrexate, Prednisolone18SFRAM725616pospos51513NANANA5A, 5BEtanercept, Methotrexate, Hydroxychlor.19SFRAF3231.20.8pospos15485.986935A, 5BNil20SFRAF52493pospos13346.541410785A, 5BNil21SFRAF46359posposNANANANANANA5A, 5BMethotrexate, Hydroxychlor.Table 2Sequence data and reactivity of monoclonal antibodies from FcRL4+ and FcRL4- B cells from RA patients.Table 2**Patient idClonecell originVHDHJHIg SCVH-mut.VH CDR3 (aa)(+)LengthCCP2CEP-1cit-vim 60-75cit-fib 36-52**1146+.A06ST (CD19+FcRL4+)3-332-26IgG16SRVGRVPDAVRYYFYGDV318146+.A07ST (CD19+FcRL4+)3-152-26IgG129ATDVFRTVVPVAIYSFYGLAV121**pospospos**neg146+.A08ST (CD19+ FcRL4+)3-114-174IgA110ARGRWGLYGDYIFDS215146+.A09ST (CD19+ FcRL4+)5-513-223IgA11ARPHYYDSLDAFDI214146+.A10ST (CD19+ FcRL4+)3-336-134IgA110AREEGTGIVATDTESDFFDS120negnegnegneg146+.A11ST (CD19+ FcRL4+)1-183-105IgA115ARRPDSSQYSNWIDP215negnegnegneg146+.A12ST (CD19+ FcRL4+)3-236-135IgA123AKDDSPIATHSSWDS215negnegnegneg146+.B01ST (CD19+ FcRL4+)3-30-33-224IgG135VRGYCSSLSCSSFDS115negnegnegneg146+.B02ST (CD19+ FcRL4+)1-463-33IgA120ARAEGAVTIDDAFDI115negnegnegneg146+.B03ST (CD19+ FcRL4+)1-692-84IgG117ARHCNNGLCFYYFDY215146+.B04ST (CD19+ FcRL4+)3-304-114IgG118VKDAYRTQSPHFNNR415146+.B05ST (CD19+ FcRL4+)4-596-136IgA121ARAGSWFLYGMDV113146+.B06ST (CD19+ FcRL4+)4-43-103IgG18TSPQGGPGSYPHDAFDV117negnegnegneg146+.B08ST (CD19+ FcRL4+)1-23-94IgG18CARLRQDFDLLTGYQLGSYYFDY223negnegnegneg146+.B12ST (CD19+ FcRL4+)1-181-266IgG326AKDQWEAYYGLDV113146+.C01ST (CD19+ FcRL4+)3-232-26IgA112ARGKARYQLPTYFYYGMDV319negnegnegneg146+.C04ST (CD19+ FcRL4+)3-533-34IgG114ARAAVDFWSGYHLEY215146+.C05ST (CD19+ FcRL4+)5-516-136IgA222TRLGSWYLHYYGVDV215146+.C06ST (CD19+ FcRL4+)3-232-156IgA115AKRVVVASNHGYYSMDV317146+.C08ST (CD19+ FcRL4+)3-213-94IgA120ARDYDVFTGYPSHFFDH317146+.C09ST (CD19+ FcRL4+)3-212-156IgG225ARDRVDIVVKEPNFYYGVDV320146+.C10ST (CD19+ FcRL4+)4-341-264IgA129ANRRRYTTRFYFDF414146+.D07ST (CD19+ FcRL4+)3-233-101IgA11AKDRGVLRYFDWLH414neg**pospos**neg146+.D08ST (CD19+ FcRL4+)4-30-43-35IgG236ASSGFFGQPYNWFDR115146+.D09ST (CD19+ FcRL4+)3-483-34IgG131ARDTRDFWSGYYTYYFDY218posnegnegneg146+.D10ST (CD19+ FcRL4+)5-514-236IgA119ARLGKTTTVTSPYYYYYGMDV221negnegnegneg146+.E01ST (CD19+ FcRL4+)1-695-124IgG112ARDSGYDEGYYFDY114negnegnegneg146+.E02ST (CD19+ FcRL4+)3-91-264IgA124AKASGLTGSFYPLDH215146+.E04ST (CD19+ FcRL4+)4-342-154IgG16ARGGHRKYCSGGSCIYYFDY420146+.E05ST (CD19+ FcRL4+)3-115-123IgA119ARDDTVAFKDALDI214negnegnegneg146+.E06ST (CD19+ FcRL4+)1-691-14IgA134ARERALCAEGCPPGDD216neg**pos**negneg146+.E07ST (CD19+ FcRL4+)5-10-13-104IgA216ARVRTYYSAGTYPFDS216146+.E08ST (CD19+ FcRL4+)3-302-86IgA121AKAWGQLAGFALYFYGLDV119146+.E12ST (CD19+ FcRL4+)3-483-34IgA126ARINYDYWSDYARFLDS217146+.F01ST (CD19+ FcRL4+)4-30-43-104IgG10AFHLGEYGSGSYYDLDY117negnegnegneg146+.F02ST (CD19+ FcRL4+)4-38-26-133IgA131ARDRGYSTNWFLGFDV216negnegnegneg146+.F04ST (CD19+ FcRL4+)3-212-84IgG119AKPTVVYGPIDY112146+.F08ST (CD19+ FcRL4+)4-38-23-34IgA122AREFEHFGSGYFPVDY216146+.F09ST (CD19+ FcRL4+)3-493-34IgA126NSRSGFGVVAPEIDH215146+.F10ST (CD19+ FcRL4+)3-231-264IgA120ATDGEGVLFDE011negnegnegneg146+.F11ST (CD19+ FcRL4+)4-593-33IgA122ARVMTVFGVVPDAFDI116146+.F12ST (CD19+ FcRL4+)3-436-194IgM3AKDISSTGWEYCFEN115146+.G01ST (CD19+ FcRL4+)3-201-264IgA115AKPSRVGAAADADY214146+.G02ST (CD19+ FcRL4+)4-313-35IgG110AREGVHATTFGMIDDQGWFDP221negnegnegneg146+.G03ST (CD19+ FcRL4+)1-461-146IgG118ARVSPGIRDDMDV213negnegnegneg146+.G04ST (CD19+ FcRL4+)3-307-274IgG14ARESGARWDVYFDY214negnegnegneg146+.G05ST (CD19+ FcRL4+)4-30-43-165IgG136ARAPPETLRGIVGNWFDP218neg**pospos**neg146+.G06ST (CD19+ FcRL4+)1-32-154IgG114VKDGGAGGANTFDH214146+.G07ST (CD19+ FcRL4+)3-335-244IgA131ARARRGDGYNQARYYYFDY419neg**pos**negneg146+.G09ST (CD19+ FcRL4+)1-186-193IgA14ARGWYSRGGGMDV213negnegnegneg146+.G10ST (CD19+ FcRL4+)1-183-164IgG110ARGWDPIVLPDYW113146+.G11ST (CD19+ FcRL4+)3-232-24IgA127AKSHLAHYVPVPAPFDF317146+.G12ST (CD19+ FcRL4+)1-31-266IgM1TRDLLDRGKYYRVAGHFYGMDV522146+.H02ST (CD19+ FcRL4+)3-303-96IgG333ARDGGENEIVTGYFGWSNKPHSVKYYHGMDV531146+.H05ST (CD19+ FcRL4+)4-613-222IgG23ARHVGRLRRDSFTTRRTTDAADDWHIDL828146+.H07ST (CD19+ FcRL4+)3-301-265IgG126AKQSATMGPNRQPR314negnegnegneg146+.H08ST (CD19+ FcRL4+)4-346-135IgA19ARGFWDSGSWFDY113146+.H09ST (CD19+ FcRL4+)4-342-216IgG18ASKGGDSVGYHYYMDV216negnegnegneg146+.H10ST (CD19+ FcRL4+)1-183-35IgA114ARGRPSTFGVVRGFDP316146-.A03ST (CD19+ FcRL4-)3-304-174IgG113TRATRVNGNLNTFDY215negnegnegneg146-.A06ST (CD19+ FcRL4-)3-93-35IgG114AKDRFGELTDLTYVGWFDP219negnegnegneg146-.A07ST (CD19+ FcRL4-)5-10-13-105IgA131ARLDTSVIRGYNWFDP216negnegnegneg146-.B05ST (CD19+ FcRL4-)4-592-153IgA17ARHRGGSPTAFDI313negnegnegneg146-.B07ST (CD19+ FcRL4-)3-154-174IgG117TTVDDYECHDY111146-.B11ST (CD19+ FcRL4-)4-42-154IgG117ARVSEAYFDPFYYDNN116146-.B12ST (CD19+ FcRL4-)1-183-94IgG130ARAPGSLRYYDWVSLYEEGDH321negnegnegneg146-.C01ST (CD19+ FcRL4-)1-463-103IgA120TSPQGGPGSYPHDAFDV117negnegnegneg146-.C07ST (CD19+ FcRL4-)1-463-36IgG129ARVTTFESGPNDFGVPDHFYYVLDV225negnegnegneg146-.C10ST (CD19+ FcRL4-)4-341-264IgA132ANRRRCTTRFYFDF414negnegnegneg146-.D03ST (CD19+ FcRL4-)3-232-84IgG122AKPLVYARLYFYYDLDY217negnegnegneg146-.D05ST (CD19+ FcRL4-)3-483-224IgG10VRDSPGWGFRYYDY214negnegnegneg146-.D06ST (CD19+ FcRL4-)4-30-43-224IgM3AAYPGDNSGRHLISPPFDN219146-.D09ST (CD19+ FcRL4-)4-30-43-224IgG126AAYGSYDRHLISPNPFYYDN220negnegnegneg146-.E04ST (CD19+ FcRL4-)3-76-136IgG225VSQQVVPC08146-.E05ST (CD19+ FcRL4-)3-76-136IgA231VSGGLQQYDVVPC013146-.E06ST (CD19+ FcRL4-)4-342-154IgA18ARGGHRKYCSGGSCIYYFDY420negnegnegneg146-.E07ST (CD19+ FcRL4-)3-742-26IgG311ARVQPQRVLVFYGMDV216146-.E08ST (CD19+ FcRL4-)3-114-174IgG116ARGAVTTPEYYFDY114negnegnegneg146-.E10ST (CD19+ FcRL4-)4-594-114IgA125ARLDYSPAFIFDS113negnegnegneg146-.E11ST (CD19+ FcRL4-)3-30-33-94IgG113ARGWERYYDWVAPGH315146-.F01ST (CD19+ FcRL4-)3-113-106IgG426ARGPSGMFGDLSPYFHYGVDV221146-.F04ST (CD19+ FcRL4-)5-10-12-155IgG119ARHGRGPSSWYDF313146-.F08ST (CD19+ FcRL4-)1-32-84IgA125ARSHQPYILLAGTPGD216negnegnegneg146-.F10ST (CD19+ FcRL4-)5-10-12-153IgA119AKAASRFDTFDI212negnegnegneg146-.F11ST (CD19+ FcRL4-)4-314-234IgG222TRGVIGLRGVPYYFDS216146-.G03ST (CD19+ FcRL4-)3-664IgG117RVDDTAVYYCARSPTGYDILTGPFDY226146-.G04ST (CD19+ FcRL4-)1-186-192IgM5ARAVAVNWYFDL112146-.G05ST (CD19+ FcRL4-)3-485-183IgM0ARGRKGYSYDAFDI314146-.G07ST (CD19+ FcRL4-)3-203-224IgG112ARGPPYYISSGYYFSFDS118146-.H01ST (CD19+ FcRL4-)4-592-214IgA122ARDDSLGGFDY111negnegnegneg146-.H02ST (CD19+ FcRL4-)3-233-225IgM2AKYYDTSGSYKACDI215146-.H04ST (CD19+ FcRL4-)3-113-224IgG125ARGFYHDGTAYYHRNQSPFDH521**Patient idClonecell originVHDHJHIg SCVH-mut.VH CDR3 (aa)(+)LengthCCP2CEP-1cit-vim 60-75cit-fib 36-52**5153+.A04SF (CD19+ FcRL4+)4-393-105IgG16ARLGGGYYYGSGYTRFDP218neg**pos**negneg153+.A08SF (CD19+ FcRL4+)3-133-91IgA116ATKPSHIYLRYFDWLLQGVRPLL423153+.A09SF (CD19+ FcRL4+)4-393-224IgG12ARYLREDYDISGLDY215negnegnegneg153+.A10SF (CD19+ FcRL4+)1-693-103IgG112ARRGYYYDYVWGDFRLTGPIEGAFDI326negnegnegnrg153+.B05SF (CD19+ FcRL4+)4-593-224IgG313AADNYYDSSEYSPYSFDS018153+.B08SF (CD19+ FcRL4+)3-483-36IgG44ASDKYDSWSRYVPYYGLDV219153+.C03SF (CD19+ FcRL4+)3-333-94IgG28ARGPDILTGGFYFDY115153+.C04SF (CD19+ FcRL4+)3-743-104IgG16VRGDLWFVELLYG113negnegnegneg153+.C06SF (CD19+ FcRL4+)1-183-224IgA12ARGSPYYYDSSGYYHYFDS219negnegnegneg153+.C09SF (CD19+ FcRL4+)4-593-36IgA13ARDKSADTLEWYYYYYGMDV220153+.C10SF (CD19+ FcRL4+)5-516-194IgA14APQSGSGWPYFDY013153+.C12SF (CD19+ FcRL4+)3-337-274IgA116ARHRGVTGLLNEPGDY316negnegnegneg153+.D01SF (CD19+ FcRL4+)3-332-214IgA11ARLLKTYCGGDCSLGY216153+.D06SF (CD19+ FcRL4+)5-513-36IgA10ARQYYDFWSDYYNSDYYYGMDV122153+.D08SF (CD19+ FcRL4+)4-343-106IgA17ARESHDHAELGYYYGMDV318153+.E01SF (CD19+ FcRL4+)4-596-134IgA17ASLPGSSTWFPFDY014153+.E03SF (CD19+ FcRL4+)3-213-104IgA110ARIRTKWFRRSSTMSSSFDY520153+.E04SF (CD19+ FcRL4+)1-692-156IgG26ARGRVPRIYYYYGMDV316153+.E05SF (CD19+ FcRL4+)1-23-223IgG17ARCDWGIYYYDSRAHGAFDF320negnegnegneg153+.E07SF (CD19+ FcRL4+)4-30-23-94IgM1ARDQFFLAALDY112153+.E11SF (CD19+ FcRL4+)1-694-176IgG24AREDYGDDYYYYGMDV116153+.F02SF (CD19+ FcRL4+)3-663-223IgG34AREYNYDSSDAFDI114153+.F04SF (CD19+ FcRL4+)1-696-64IgG25ARSVQNLRYLGYYFDY216153+.F07SF (CD19+ FcRL4+)3-153-94IgG15TSSLVLRYFDWSTHSSDY218negnegnegneg153+.G01SF (CD19+ FcRL4+)3-151-14IgG14TTALNWNWDYYDY013negnegnegneg153+.G07SF (CD19+ FcRL4+)3-92-154IgG29VASYWRGYYFDY112153+.H01SF (CD19+ FcRL4+)3-333-36IgG18AKVAGYDFWSGPGGYYYSMDV121153+.H02SF (CD19+ FcRL4+)1-182-155IgM4ARDSGGSWLDP111153+.H06SF (CD19+ FcRL4+)3-741-74IgG17ARGGWGPRYNWNQGAVDY218**pospospos**neg153+.H11SF (CD19+ FcRL4+)3-114-116IgA118ARQSAYANYYYKGMDV216153-.A03SF (CD19+ FcRL4-)4-343-222IgA114ARGLTFSYYDSSGFGYYYWYFDL123negnegnegneg153-.A04SF (CD19+ FcRL4-)1-182-156IgG17ARDRHCSGGTCYPYHYGMDV420153-.A06SF (CD19+ FcRL4-)4-593-105IgG45ARTTTIRGVINWFDP215153-.A07SF (CD19+ FcRL4-)1-696-195IgM1ARDFQRTSTVTRGIAVGSRFDP422153-.A12SF (CD19+ FcRL4-)5-512-23IgG23ARHLEYPHYVFDF313153-.B07SF (CD19+ FcRL4-)4-44-174IgM4ARGGIWNDYGDFYPYYFDY119153-.C04SF (CD19+ FcRL4-)3-232-216IgG26AKEDYHFGRVD311153-.C07SF (CD19+ FcRL4-)1-186-135IgG35ARDGAMGHPDFWQQLVASWFDP222153-.C09SF (CD19+ FcRL4-)1-465-184IgG18AKSRGYSYGYFDY213153-.C11SF (CD19+ FcRL4-)5-515-126IgG26ARLPHYDWYYYYAMDV216153-.C12SF (CD19+ FcRL4-)4-393-164IgG112ARRSVYDANFDF212negnegnegneg153-.D11SF (CD19+ FcRL4-)1-83-225IgM2ARAPYYYDSSGYYRGWFDP219153-.D12SF (CD19+ FcRL4-)3-215-244IgA28ARDLVEMATIIGHISY216153-.E12SF (CD19+ FcRL4-)4-42-154IgG110ARVVSEAAYFDN112negnegnegneg153-.F02SF (CD19+ FcRL4-)3-493-106IgG112SRVLRVVWGGRYYCMDV317negnegnegneg153-.F03SF (CD19+ FcRL4-)4-593-104IgA15ARVIMFTMVRGVQYYFDY218153-.F05SF (CD19+ FcRL4-)4-343-103IgA15ARGREVIMVRGVMKGTEAFDI421153-.F06SF (CD19+ FcRL4-)4-303-164IgA18ARGGREMLTIGGVVLSAFDF220negnegnegneg153-.F09SF (CD19+ FcRL4-)3-91-14IgA17VKDITWNRLWVFDS214153-.F10SF (CD19+ FcRL4-)4-41-144IgG17ARDKGNQPFFDY212negnegnegneg153-.F11SF (CD19+ FcRL4-)1-243-224IgA114ATVQNYFDSSGRVTPKSDFDY221153-.F12SF (CD19+ FcRL4-)3-483-164IgG111AGGRSYDYFDY111negnegnegneg153-.G02SF (CD19+ FcRL4-)3-92-154IgM1AASYWRGYYFDY112153-.G06SF (CD19+ FcRL4-)3-73-104IgG18ARGESGGWFGEWVDY115negnegnegneg153-.G08SF (CD19+ FcRL4-)4-614-235IgG25ATYAMGYGGKGS112153-.G12SF (CD19+ FcRL4-)3-235-244IgG14AAPPDGYNSEGYFDY015negnegnegneg153-.H01SF (CD19+ FcRL4-)3-493-223IgG23CREEKDYYDRPRDAFDI417153-.H01SF (CD19+ FcRL4-)1-23-35IgG35ARGIGFNSWSGYPNWFDL118153-.H04SF (CD19+ FcRL4-)3-233-94IgM9ATVSGWGGH19153-.H06SF (CD19+ FcRL4-)5-513-34IgG17ARHERYYDFWSGYYTEFDY319negnegnegneg153-.H09SF (CD19+ FcRL4-)1-183-164IgG111ARDLGFTFGGVMGY114153-.H10SF (CD19+ FcRL4-)1-83-36IgG46ARGINDFWSDYGMDV115153-.H11SF (CD19+ FcRL4-)3-96-66IgG26AKDKWKLAGASGGMDV316**Patient idClonecell originVHDHJHIg SCVH-mut.VH CDR3 (aa)(+)Length**3423+.A01SF, CD19+FcRL4+4-314-173IgG16ARGLDTHYGDYELDAFDI218423+.A02SF, CD19+ FcRL4+1-695-246IgA121TREISAKGANYNYYGMDV218423+.A05SF, CD19+ FcRL4+3-493-223IgG112ARDRWIVVVPEGGASDI217423+.A06SF, CD19+ FcRL4+1-695-184IgG217AREEAVDTAMLWYY114423+.A07SF, CD19+ FcRL4+1-695-244IgG118CAREGLYIATAFFDL115423+.A11SF, CD19+ FcRL4+4-30-43-223IgA127ATQSLGSSGYYRAFDI116423+.A12SF, CD19+ FcRL4+5-10-13-221IgA222AKDLLHFPYYYDSSDYYWPAVYFDL225423+.B04SF, CD19+ FcRL4+3-301-264IgG25ASGPRSGRKDYFDD314423+.B05SF, CD19+ FcRL4+1-696-194IgA113VRGSSGWNFDH211423+.B06SF, CD19+ FcRL4+4-393-36IgA111ASSITIFGVVKXXXGMDV118423+.B11SF, CD19+ FcRL4+3-495-244IgA122AREITSRNGYNHFAY315423+.B12SF, CD19+ FcRL4+3-535-186IgA116ASGGYSYGLDYYYAMDV017423+.C01SF, CD19+ FcRL4+1-463-102IgA15ARDQSITMVRGGPPDWNFDL220423+.C05SF, CD19+ FcRL4+4-591-204IgG210AKSSSPYDWNAPKADY216423+.C07SF, CD19+ FcRL4+3-206-136IgG111SRDVGSSFPPYYSYAMDV118423+.D05SF, CD19+ FcRL4+4-43-36IgG32AREGVGSTQGPYYYMDV117423+.D10SF, CD19+ FcRL4+4-593-164IgG16AAEVMNTDGDVDY013423+.E01SF, CD19+ FcRL4+4-396-134IgG413ARFPAGYAGSWYVDY115423+.E02SF, CD19+ FcRL4+3-216-134IgG212ASSPSGPGAAVFDY014423+.E05SF, CD19+ FcRL4+1-461-16IgG14AKESTATIGTPPEVNYYYGMDV122423+.E08SF, CD19+ FcRL4+3-303-163IgG123ARETNSYAFDI111423+.F02SF, CD19+ FcRL4+4-483-104IgG114AGVERDYVSH210423+.F05SF, CD19+ FcRL4+4-30-23-104IgG112ARVRWGSGSKIDY313423+.F10SF, CD19+ FcRL4+1-465-184IgA217ARGRGSSYGVTGFDY215423+.G01SF, CD19+ FcRL4+1-463-104IgG217ARGSGSGSYYNIDY114423+.G03SF, CD19+ FcRL4+4-43-94IgG16ARDPRRYHILTGHYEGGPSDY521423+.G07SF, CD19+ FcRL4+3-302-156IgG134AKRTGPVVVSRGGLDV316423+.G10SF, CD19+ FcRL4+3-30-35-185IgA11AREGGGYSYADNWFDP116423+.G12SF, CD19+ FcRL4+3-486-191IgG46ARDLPSRGAVAEDFDL216423+.H08SF, CD19+ FcRL4+4-596-193IgG15AREDPGQTPSGDGPDDAFDI120423+.H09SF, CD19+ FcRL4+4-316-64IgM30AARIASRYFDS211423+.H10SF, CD19+ FcRL4+1-692-153IgG18ASDVARYCSGGSCYSHAFDI220423+.H11SF, CD19+ FcRL4+1-695-243IgM24ARTGEMATTPNAFDIW116423-.A02SF (CD19+ FcRL4-)1-21-263IgA115ARGWGAAQVVFDM113423-.A05SF (CD19+ FcRL4-)4-343-34IgG29ARRTTAYFDFWSDYYFDS218423-.A09SF (CD19+ FcRL4-)1-21-264IgA112ARGFRSGSYPGY212423-.B01SF (CD19+ FcRL4-)3-154-234IgG118ATVRRSLSPLKY312423-.B10SF (CD19+ FcRL4-)4-312-216IgA212ARFRHWYYYIDV312423-.B11SF (CD19+ FcRL4-)4-393-104IgA113AGLYGDLFPGVMRYFDP117423-.C02SF (CD19+ FcRL4-)3-233-104IgA119ANAGTGYLPFDY012423-.C03SF (CD19+ FcRL4-)3-333-106IgM4ASRGGVGGYYVKDYGMDV218423-.C04SF (CD19+ FcRL4-)5-513-226IgG12ARLRYYYDSSGYYYMNNYYYYYMDV225423-.C05SF (CD19+ FcRL4-)3-235-184IgG227AKDVVDSVMGLPFDY115423-.C09SF (CD19+ FcRL4-)3-333-165IgA13AREGDLIPDRFDP213423-.C12SF (CD19+ FcRL4-)1-182-26IgM5SRVGRVPDAVRYYFYGDV318423-.D01SF (CD19+ FcRL4-)1-695-125IgA129ARDRRGGNRRRENWFDP617423-.D02SF (CD19+ FcRL4-)3-436-134IgG29AAAPGRRFDY210423-.D03SF (CD19+ FcRL4-)4-312-214IgG116ARGSGSGYDLAYCGGDCYFLLDK223423-.D06SF (CD19+ FcRL4-)4-30-43-224IgG13AAYPGSYYDNSGRHLISPPFDN222423-.E02SF (CD19+ FcRL4-)3-485-123IgG220ARGGYSGYLLTHDAFDI217423-.E07SF (CD19+ FcRL4-)3-303-34IgG112ANEVDFWSGYYDY013423-.E08SF (CD19+ FcRL4-)3-493-106IgG118SRVDRVVRGGRYYYYCMDV419423-.E12SF (CD19+ FcRL4-)4-616-194IgM6ARVPRGWYYIDY212423-.F03SF (CD19+ FcRL4-)3-232-84IgG110AKPLVYARLYFDY213423-.F04SF (CD19+ FcRL4-)3-336-135IgG115ARDPPTSQYSSTWWTDRGFDH321423-.F06SF (CD19+ FcRL4-)3-112-214IgG122AREGPIVVVPVV112423-.F07SF (CD19+ FcRL4-)1-23-104IgG314ASGVNADGEGGPPTVGY017423-.F10SF (CD19+ FcRL4-)5-10-12-153IgG110AKAASRFDTFDI212423-.G03SF (CD19+ FcRL4-)3-336-194IgG132ARDRQWLLDY210423-.G05SF (CD19+ FcRL4-)3-93-165IgM1AKGGWITLGSWFDP114423-.H03SF (CD19+ FcRL4-)1-466-194IgG118ARVVTDTAGWYHFDY215423-.H04SF (CD19+ FcRL4-)1-462-24IgG312ARGRLPAAIRIDFDY315423-.H06SF (CD19+ FcRL4-)3-30-36-193IgG18AKDGKAVDGFSGVLEM216423-.H07SF (CD19+ FcRL4-)4-313-104IgG129AGVERDYVSH210423-.H11SF (CD19+ FcRL4-)4-30-45-186IgG119ARERSYGRQYHYGMDV416**Patient idClonecell originVHDHJHIg SCVH-mut.VH CDR3 (aa)(+)Length**203+.A02ST, CD19+ FcRL4+4-596-131IgA11ARYFFGGMSAAGSYFQH21703+.A03ST, CD19+ FcRL4+5-513-225IgG226ARLSGYYDSSGYYYPYNWFDS12103+.A09ST, CD19+ FcRL4+5-513-103IgG119VRHILWFGESDSFDI21503+.B01ST, CD19+ FcRL4+1-32-214IgG325ARSHQPYILLAGRPGV31603+.B02ST, CD19+ FcRL4+3-334-176IgA125CAGDYITRPNFSYYYYGMDV12003+.B03ST, CD19+ FcRL4+3-30-35-124IgG11AKYHVDIVATSLEYFDY21703+.B04ST, CD19+ FcRL4+3-213-35IgA14ARVWEDWFDP11003+.B05ST, CD19+ FcRL4+3-485-246IgG113AKDQPHGHIYYGLDV31503+.B06ST, CD19+ FcRL4+4-343-224IgM14ARDREYYDSRGYYSFDY31703+.B09ST, CD19+ FcRL4+1-183-224IgG113AREFPYDSSGYFPGGGDY11803+.B09ST, CD19+ FcRL4+4-346-134IgG19ARGPPRAVPGTARRRYFDS51903+.C02ST, CD19+ FcRL4+3-332-155IgG128ARHGRGPSSWYDF31303+.C03ST, CD19+ FcRL4+1-692-156IgG14ARGYCSGGSCFDHYYYYGMDV22103+.C10ST, CD19+ FcRL4+1-691-264IgG116ARGFQVGTITGFDY11403+.C11ST, CD19+ FcRL4+3-202-24IgA111AKSLIGVESSFDS11303+.C12ST, CD19+ FcRL4+3-30-33-224IgG110ARGKDYYDSTGYYWGILDD21903+.D02ST, CD19+ FcRL4+3-211-264IgG12ARDRRVPYIVGATDFDY31703+.D04ST, CD19+ FcRL4+3-333-106IgA231ARGPSGMFGDLSPYFHYGVDV22103+.D06ST, CD19+ FcRL4+3-332-156IgA124ARDREAATPKYGMDV31503+.D07ST, CD19+ FcRL4+3-746-192IgG16AREVEQWLEHGVLWYFDL21803+.D08ST, CD19+ FcRL4+1-34-176IgG313AGDYITRPNFSYYYYGVDV11903+.F01ST, CD19+ FcRL4+4-395-243IgG110ARDREMGHQGIFDI31403+.F03ST, CD19+ FcRL4+1-32-26IgG49SRDRSISWDGDGMDVW21603+.F04ST, CD19+ FcRL4+4-392-84IgG113ARDKGNQPFFDY21203+.F05ST, CD19+ FcRL4+3-333-106IgA129ASRGGVGGYYVKDYGVDV21803+.F07ST, CD19+ FcRL4+4-43-36IgG16ARVSSAKTTFGVTTTWGGMDV22103+.F08ST, CD19+ FcRL4+3-204-174IgA14ARGGGPGDKVRGDY31403+.G03ST, CD19+ FcRL4+3-662-26IgA11ARGGTISRYYYFGMDV21603+.G07ST, CD19+ FcRL4+1-696-196IgA119ARGAVAGRHYYFGLDV31603+.G08ST, CD19+ FcRL4+1-696-135IgG24TREAAAAGRNNWFDP21503+.G12ST, CD19+ FcRL4+1-32-84IgG213ARSHQPYILLAGTPGD21603+.H01ST, CD19+ FcRL4+4-43-224IgG418CACRYLGLDY11003+.H04ST, CD19+ FcRL4+4-344-236IgG19CARVPEVVTPRYYYYFGLDV22003-.A01ST (CD19+ FcRL4-)3-92-154IgG333VKDGGAGGANTFDH21403-.A02ST (CD19+ FcRL4-)1-692-216IgG129ASKGGDSVGYHYYMDV21603-.A03ST (CD19+ FcRL4-)3-236-134IgA17AKGPYSSSWYGAPFDY11603-.A04ST (CD19+ FcRL4-)1-695-243IgG122ARDREMGHQGIFDI31403-.A06ST (CD19+ FcRL4-)1-696-134IgG14ARARIAAAGNPGSFDY21603-.A08ST (CD19+ FcRL4-)4-593-104IgG14ARDSSYEDSVYFDY11403-.A12ST (CD19+ FcRL4-)1-182-24IgG44ARDEFQLPDY11003-.B06ST (CD19+ FcRL4-)3-231-266IgG128AKSWAILQFEPLYGMDV11703-.B11ST (CD19+ FcRL4-)3-533-166IgG115TRERPHEYVWGSFRRHYGMDV62103-.C01ST (CD19+ FcRL4-)3-494-175IgA129TIVFPELPRVPLP11303-.C03ST (CD19+ FcRL4-)3-233-221IgG214AKDRAGNNSGYYYVGEYFQH32003-.C05ST (CD19+ FcRL4-)4-342-84IgG14ARGRETYCAAGVCSSKGKRPDYFDY52503-.C08ST (CD19+ FcRL4-)3-30-33-34IgA231AREFEHFGSGYFPVDY21603-.C09ST (CD19+ FcRL4-)3-213-223IgG230ARDRFPSDDYDGPEGFDL21803-.D04ST (CD19+ FcRL4-)4-30-43-34IgG129ARASTLEWSYGSFDY11503-.D05ST (CD19+ FcRL4-)3-233-224IgG119AKADYSDSSGYKDY21403-.D07ST (CD19+ FcRL4-)3-743-35IgG113ASSYRIWSFDP11103-.D08ST (CD19+ FcRL4-)3-232-84IgA11AKPMVYARLYFDY21303-.D11ST (CD19+ FcRL4-)3-233-94IgG119AKDFTRYFDWLLRDLFDY31803-.E07ST (CD19+ FcRL4-)3-235-244IgG115ARDRMACDY2903-.E08ST (CD19+ FcRL4-)3-113-224IgG218ARDLTGMNSDSSGYYSDY11803-.E11ST (CD19+ FcRL4-)3-233-106IgG122AKAGQSPDMVRGVIRWGPKPEPKNSYYGMDV53103-.F08ST (CD19+ FcRL4-)3-301-264IgA123AKGVGALQAGLGSGVYYFNY12003-.F10ST (CD19+ FcRL4-)4-395-245IgM25ARRGHYVWFDP31103-.G07ST (CD19+ FcRL4-)3-203-224IgM8ARGPPYYISSGYYFSFDS11803-.G11ST (CD19+ FcRL4-)3-73-95IgA16ARTPGTFHTHNWFDP31503-.H04ST (CD19+ FcRL4-)4-313-105IgG125ARVVPAHHFPSGGHSSSAFNWFDP42403-.H10ST (CD19+ FcRL4-)3-333-34IgA115TRSLGYCTRSTCYSHEHYDH520**Patient idClonecell originVHDHJHIg SCVH-mut.VH CDR3 (aa)(+)Length**6508+.A05SF (CD19+ FcRL4-)1-82-15518ARGHGHCSDSGCFNNWFDP319508+.A07SF (CD19+ FcRL4-)3-663-9415ARSPTGYDILTGPFDY116508+.A10SF (CD19+ FcRL4-)3-73-10632ARDNARAWFSHYYYGMDV318508+.B03SF (CD19+ FcRL4-)3-113-1060ARDLRYYGSGMYYTYYYYGMDV222508+.D05SF, CD19+ FcRL4+3-333-10628ASRGGVGGYYVKDYGMDV218508+.D11SF (CD19+ FcRL4+)3-113-10633ARMWFGDDHYYYGLDI216508+.E03SF (CD19+ FcRL4+)4-313-3418ARGQRGAILVHGYIPFFDF319508+.E06SF, CD19+ FcRL4+3-306-6420AKDPHSSSLISPPLFGY217508+.E09SF (CD19+ FcRL4+)3-743-3119ARVFKGWSSWYQGSPSEYFQH321508+.E10SF (CD19+ FcRL4+)1-695-18521ARGRTYTYGPMRWFDP316508+.E11SF (CD19+ FcRL4+)3-486-13528ARGQGRIEYNWFDL214508+.F02SF, CD19+ FcRL4+4-344-11612ARPTHSTVTMWYFGMDV217508+.F04SF, CD19+ FcRL4+3-303-10519ARDPINYYGSGSYSWNWIDP120508+.F09SF, CD19+ FcRL4+3-113-963ASPSGNPNPFTMDV014508+.F11SF, CD19+ FcRL4+3-153-16210AREVTPHWYFDL212508+.F12SF, CD19+ FcRL4+1-462-15412ARGGPFTNPLCSASTCYYFDS121508-.B04SF (CD19+ FcRL4-)3-72-21417ARAADYGPVAGLFEY115508-.B09SF (CD19+ FcRL4-)1-83-10417AFHLGEYGSGSYYDLDY117508-.B10SF (CD19+ FcRL4-)3-215-12528ARVWVTGAAIFGDNWFDP118508-.C04SF (CD19+ FcRL4-)1-83-3429ARAAVDFWSGYHLEY215508-.C07SF (CD19+ FcRL4-)1-242-1549AIMGALYCSGGDCYLRGAGEFDY123508-.D06SF (CD19+ FcRL4-)3-482-8514ARGLGRLCGADNCYNWFDP219508-.D08SF (CD19+ FcRL4-)3-332-2613ARARYSSSSYGMDV214508-.D10SF (CD19+ FcRL4-)3-236-1947AREGIPVAGTDY112508-.E12SF (CD19+ FcRL4-)3-153-3413TAYRITPFGVLTGFGERPVDY221508-.F03SF (CD19+ FcRL4-)4-612-2417ARIKGGYCSYTNCKRPVPFDY421508-.F08SF (CD19+ FcRL4-)4-30-45-1244ATAPRSPTGYDSFYLDS117508-.G05SF (CD19+ FcRL4-)3-485-18317ARGRKGYSYDAFDI314508-.G08SF (CD19+ FcRL4-)3-304-1755AQDRVAALTRGGLGWFDP218508-.G09SF (CD19+ FcRL4-)1-694-1144ARELYSNYFF110508-.H07SF (CD19+ FcRL4-)4-347-2744ARLRPRLRGDLDS413508-.H08SF (CD19+ FcRL4-)1-186-1944ARTTGGDSGWFDHMDF216508-.H11SF (CD19+ FcRL4-)3-433-22636AKGLRKTDVYYDSSGFGYYYGMDV324508-.H12SF (CD19+ FcRL4-)1-243-944ATENRFRHFWYGFDF315**Patient idClonecell originVHDHJHIg SCVH-mut.VH CDR3 (aa)(+)Length**4531+.A01SF (CD19+ FcRL4-)3-211-1415ARCRPGSTSPEF212531+.B07SF (CD19+ FcRL4+)3-743-10428ARERSRIIDY310531+.B08SF (CD19+ FcRL4+)4-394-1726TRQWGSDYGDYWYFDL116531+.B09SF (CD19+ FcRL4+)4-393-3611SRDQRITILGVVSVWFGMDV220531+.C02SF (CD19+ FcRL4+)1-182-2415ARALLDGYCTGSSCAVGSMDY121531+.C07SF (CD19+ FcRL4+)3-336-19219AGSLSSGWHGNRYFDL216531+.C08SF, CD19+ FcRL4+4-346-6417AKGSTSSLYRHTMPYQY317531+.C12SF (CD19+ FcRL4+)3-91-1422ARDAKYYFDY210531+.D03SF (CD19+ FcRL4-)4-341-2635ARSWELLLGAFDI113531+.G01SF, CD19+ FcRL4+1-696-13628ATAGYTSRWNPSFYHGLDV219531+.G02SF, CD19+ FcRL4+1-33-10423ARDYGSGNSGYFDY114531+.G03SF, CD19+ FcRL4+3-334-1743VTDYGDYVELGY012531+.G04SF, CD19+ FcRL4+3-156-19615ARGWLEPFYYYGVDV115531+.G11SF, CD19+ FcRL4+3-113-10515ARDLLVHGVAISNWFDP217531+.H07SF, CD19+ FcRL4+4-45-12619ARYSGFYYHYGMDV214531-.D10SF (CD19+ FcRL4-)3-233-3625AKGGSGAFWSGYYKNYYYYYMDV223531-.D11SF (CD19+ FcRL4-)1-463-3614ARVTFESNDFGPDHFYYVLDV221531-.D12SF (CD19+ FcRL4-)3-691-2643ARHNGSYKKGYYFDY415531-.E01SF (CD19+ FcRL4-)3-483-16422AGGRSYDYFDY111531-.E02SF (CD19+ FcRL4-)3-234-2342AKEVQTEGGFDY112531-.E03SF (CD19+ FcRL4-)4-42-15423ARVVSEAAYFDN112531-.E09SF (CD19+ FcRL4-)3-115-18415ARRGGYSYRKDYFDS415531-.E12SF (CD19+ FcRL4-)3-235-1844AKDKWEGAMNPHYFDF316531-.F02SF (CD19+ FcRL4-)3-333-1651ARETFERIRLGEPNWFDP318531-.F03SF (CD19+ FcRL4-)4-343-3425TRDLSRKIFGVVKPAFYFDY420531-.F05SF (CD19+ FcRL4-)3-483-2245AREGEGDLYYYDSSGYYYL119531-.F07SF (CD19+ FcRL4-)1-23-2233ASKKEGVLPLDPFDI215531-.G03SF (CD19+ FcRL4-)4-314-1162GRTLATVPMDV111531-.G11SF (CD19+ FcRL4-)3-236-1949AKGSVAGPFDY111531-.H07SF (CD19+ FcRL4-)1-183-339ARAEGAVTIDDAFDI115531-.H08SF (CD19+ FcRL4-)4-313-10312ARDGAGRDAFDM212Table 3Number of sequences and recombinant monoclonal antibodies generated from FcRL4+ and FcRL4- B cells respectively.Table 3**Patient IDSampleDiagnosis**CCP2RF**FcRL4Number of sorted 96-well platesNumber of retrieved sequencesNumber of ab clonedNumber of ab. expressed**1STRApospospositive1593426negative13323172STRApospospositive133NDNDnegative128NDND3SFRAnegnegpositive133NDNDnegative132NDND4SFRAnegnegpositive115NDNDnegative116NDND5SFRApospospositive1302210negative13325106SFRAnapospositive116NDNDnegative118NDND

2. Experimental design, materials and methods {#s0010}
=============================================

More detailed information can be found in Ref. [@bib1].

2.1. Experimental design {#s0015}
------------------------

FcRL4+ and FcRL4- B cells were sorted from synovial fluid and tissue from RA patients. Synovial fluid derived B cells were analysed for their gene expression profile by RNAseq. Immunoglobulin variable region genes from single sorted B cells were sequenced and expressed as components of recombinant monoclonal antibodies. These were investigated for their reactivity with autoantigens. Amplification of sections of Ig constant regions was used to identify Ig isotype usage.

2.2. Materials and methods {#s0020}
--------------------------

Cells from 4 SF and 2 ST samples were stained for CD19 and FcRL4 and sorted either as single cells or as cell populations. Individual IgH and IgL chain gene rearrangements were PCR-amplified independently. For identification of Ig isotypes, amplification of IgH chains with reverse primers specific for the constant regions of all human Ig classes and sequencing was used. Cloning of the Ig genes into expression vectors and antibody production and purification were performed. Antibody reactivity against citrullinated peptides was determined by ELISA. For gene expression analysis RNA sequencing was carried out on sorted FcRL4+ and FcRL4- B cells from 4 SF samples. Preamplification prior to Illumina Truseq library preparation was performed using the SMARTer amplification using olig(dT) primed reactions. Library prep was carried out using the Illumina TruSeq Stranded prep kit and sequenced on the Illumina HiSeq. 2000/2500 platform. Data were analysed as detailed in [@bib1].
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